AXSM FY 2023 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$271M+440.8% YoY

Gross Profit

$245M90.4% margin

Operating Income

-$232M-85.7% margin

Net Income

-$239M-88.4% margin

EPS (Diluted)

$-5.27

Cash Flow

Operating Cash Flow

-$145M

Free Cash Flow

-$146M

Stock-Based Comp.

$63M

Balance Sheet

Total Assets

$588M

Total Liabilities

$397M

Stockholders' Equity

$191M

Cash & Equivalents

$386M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$271M	$50M	+440.8%
Gross Profit	$245M	$45M	+445.4%
Operating Income	-$232M	-$180M	-28.9%
Net Income	-$239M	-$187M	-27.8%